On April 2, 2026, BioAtla, Inc. (the "Company") filed a certificate of merger with the Secretary of State of Delaware, marking a significant step in its previously announced Agreement and Plan of Merger with BA Merger Sub, Inc., a wholly owned subsidiary of the Company. This merger is set to take effect on April 6, 2026, at 12:01 a.m. Eastern Time. Under the terms of the merger, every fifty shares of the Company's common stock will be converted into one share of common stock of the surviving corporation, which will be BioAtla, Inc. This strategic move is expected to streamline operations and enhance shareholder value, reflecting the Company's commitment to growth and efficiency in the competitive biopharmaceutical landscape. The details of the merger are outlined in the Certificate of Merger, which has been filed as Exhibit 99.1 to the Current Report on Form 8-K. The Company continues to focus on its innovative therapies and expanding its market presence, positioning itself for future success.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.